UBS has recently reduced Royalty Pharma plc (RPRX) stock to Neutral rating, as announced on June 3, 2024, according to Finviz. Earlier, on June 14, 2022, UBS had resumed the stock to Buy, setting a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...

Bristol Myers Squibb is the century-old pharmaceutical giant that markets the oral blood thinner Eliquis in partnership with ...

On Tuesday, Royalty Pharma plc (RPRX) stock saw a modest uptick, ending the day at $27.71 which represents no change from the prior close of $27.71. The stock opened at $27.71 and touched a low of $27 ...

Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed’s recent rate cut. To ...

EQS-News: BRAIN Biotech AG / Key word (s): Contract BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator 20.09.2024 / 19:50 CET/CEST ...

In a federal tax court petition, Abbott rejects numerous "arbitrary, capricious and unreasonable" determinations the IRS made ...

Most readers would already be aware that Royalty Pharma's (NASDAQ:RPRX) stock increased significantly by 6.7% over ...

Ascendis' TransCon CNP showed similar efficacy to BioMarin's Voxzogo but offers once-weekly dosing. Learn more on BMRN and ...

Despite revenue and cash flow declines, Franco-Nevada reported record margins with an 88.7% cash margin, benefiting from ...

TORONTO, ON / ACCESSWIRE / September 27, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) ...